克里唑蒂尼
间变性淋巴瘤激酶
医学
碱性抑制剂
基因重排
内科学
癌症研究
肿瘤科
病理
基因
胸腔积液
恶性胸腔积液
生物化学
化学
作者
Till‐Martin Theilen,Jan Soerensen,Konrad Bochennek,Martina Becker,Dirk Schwabe,Udo Rolle,Thomas Klingebiel,Thomas Lehrnbecher
摘要
Inflammatory myofibroblastic tumor (IMT) and its subtype epithelioid inflammatory myofibroblastic sarcoma (EIMS) are rare soft-tissue tumors. As about 50% of IMT and 100% of EIMS contain activating rearrangements of the anaplastic lymphoma kinase (ALK) gene, targeted kinase inhibition of ALK by compounds such as crizotinib is a potential treatment option. We performed a literature review and analyzed a total of 30 patients with IMT/EIMS treated with crizotinib. A total of 12 patients achieved complete or partial remission. As preliminary data are promising, a prospective study evaluating crizotinib treatment in patients with unresectable/multifocal ALK+ IMT/EIMS is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI